Jason V Coloma

CEO Jason V Coloma sold 27,858 shares for $725,494.63 via scheduled 10b5-1 plan at MAZE.

CEO Jason V Coloma executed 3 separate sales totaling 27,858 shares for $725,494.63 on 2026-06-22 and 2026-06-23 at an average price of $26.04, reducing his holdings by 8.0% to 319,079 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, meaning it was scheduled rather than discretionary. At the time of sale, MAZE was trading -50.3% below its 52-week high of $53.65, and the company reported negative net income of $-24,208,000.00 against revenue of $20,000,000.00 in its latest quarter. His prior trades at MAZE (3 separate sells on 2026-05-26, 2026-05-22, and 2026-05-22) showed 30-day returns of -1.2% on the measurable two, though the plan-driven structure removes any inference about timing judgment from this specific filing.

CEO Jason V Coloma sells 32,564 shares for $847,048.18 via pre-arranged 10b5-1 plan; stock down 51.4% from 52-week high, company unprofitable.

Jason V Coloma, CEO of Maze Therapeutics, executed 3 separate sales totaling 32,564 shares for $847,048.18 between 2026-05-22 and 2026-05-26, reducing his holdings by 8.5% from 383,551 shares to 350,987 shares. This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, making it scheduled rather than discretionary. The sales occur in a challenging context: the stock has declined 51.4% from its 52-week high of $53.65 to the current price of $26.05, and the company reported negative net income of $-24,208,000.00 against revenue of $20,000,000.00 in the latest quarter, indicating ongoing unprofitability. The scheduled nature of the plan prevents attribution of timing intent to the CEO, but the magnitude of the decline and persistent losses merit investor attention to the company's path to profitability.